Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
A phase 1/2 trial of LNTH2403 Phase 1 dose in osteosarcoma, run by Lantheus Medical Imaging, now recruiting.
Overview
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) is a phase 1/2 interventional study registered as NCT07357519 by Lantheus Medical Imaging, with 55 participants planned, started 2026-02-03 and due to reach its primary completion in 2027-08. Interventions recorded: LNTH2403 Phase 1 dose and Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D)..
Setting
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, -Radiation Dosimetry, and Preliminary Anti-Neoplastic Activity of LNTH-2403, a LRRC15-targeted 177Lutetium-labeled Monoclonal Antibody, in Participants With Relapsed / Refractory Osteosarcoma
Phase
Phase 1/2
Sponsor
Lantheus Medical Imaging
Registry
Enrolled
55
Similar pages
not linked directly; found by shared links- TrialStudy to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Shares Osteosarcoma and the tag pipeline.
- TreatmentCobolimab
Shares Osteosarcoma and the tag pipeline.
- TreatmentHS-20093
Shares Osteosarcoma and the tag pipeline.
- TreatmentVactosertib
Shares Osteosarcoma and the tag pipeline.